[go: up one dir, main page]

CA2535550A1 - Treatment for acne vulgaris and method of use - Google Patents

Treatment for acne vulgaris and method of use Download PDF

Info

Publication number
CA2535550A1
CA2535550A1 CA002535550A CA2535550A CA2535550A1 CA 2535550 A1 CA2535550 A1 CA 2535550A1 CA 002535550 A CA002535550 A CA 002535550A CA 2535550 A CA2535550 A CA 2535550A CA 2535550 A1 CA2535550 A1 CA 2535550A1
Authority
CA
Canada
Prior art keywords
treatment
acne vulgaris
ethoxylate
composition
exchanged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002535550A
Other languages
French (fr)
Inventor
William M. Yarbrough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
William M Yarbrough Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2535550A1 publication Critical patent/CA2535550A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A treatment for Acne Vulgaris is provided for in a topical treatment. According to the invention, a method is provided for applying composition substances to the infected area, working the composition into the infected area, and removing the composition from the infected area. The composition comprises at least one ethoxylate in combination with Sodium Lauroyl Sarcosinate. Alternatively, the ethoxylate can be exchanged for a methoxylat e or a propoxylate. An inert scrubbing agent, such as polyethylene beads, can also be included. Acetylated lanolin alcohol, sodium Lauroyl Sarcosinate, EDTA, a foam stabilizer, and water can also be added to the composition to assist performance.

Description

1 Invention: Treatment for Acne Vulgaris and Method of Use 2 Inventor: William M. Yarbrough 3 I. FIELD OF THE INVENTION
4 The present invention relates to a composition including surfactants for the treatment of acne vulgaris. Methods of use are also included 6 TI. BACKGROUND OF THE INVENTION AND PRIOR ART
7 Acne vulgaris (or "acne") is a disorder of the sebaceous glands. It is 8 characterized by lesions that are either non-inflammatory or inflammatory papules and 9 nodules. Non-inflammatory papules may be open, commonly referred to as "blackheads", or closed, commonly referred to as "whiteheads". As a group, non-11 inflammatory. papules are called comedones. Closed comedones can lead to 12 inflammatory nodules, papules, and pustules. Severe cases of acne vulgaris can lead to 13 scars characterized by pitting.
14 It is believed that acne results from partial rupture of a partially inflamed follicle. The follicle then spills its components, thereby resulting in the development of a 16 perifollicular inflammatory process. Generally, fresh lesions are sterile, but later gram-17 positive diptheroids are present. Many times the skin will have a greasy look to it; this is 18 probably due, at least in part, to the release of fatty acids during lipolysis induced by P.
19 acnes.
Acne can be a serious problem. It generally manifests itself during adolescence 21 and spontaneously resolves in the late teens or early twenties; although for some, it can be 22 a life long problem. Mild to moderate acne is most often treated with topical agents.

INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use INVENTOR: . William Yarbrough 1 More severe cases are treated with incision and drainage of lesions, ultraviolet light 2 therapy, and systemic antibiotics.
3 The prior art is replete with compositions for use in the treatment of acne.
4 Topical agents, such as benzoyl peroxide, are thought to decrease bacteria and are often used in the treatment of acne. These treatments are found in many forms, lotions, gels, 6 pads, etc. and are generally available over the counter. Retinol in various forms has been 7 more recently proposed by various Inventors. There are also many soaps used in the 8 treatment of acne. A major shortcoming of most of the prior art is that they often do not 9 penetrate sufficiently and they leave the skin dry.
II. OBJECTS OF THE INVENTION
11 It is an obj ect of the present invention to provide a treatment that helps to alleviate 12 the local signs and symptoms caused by acne vulgaris.
13 It is a further object of the present invention to provide a method of use of the 14 present inventive treatment.
It is yet another object of the present invention to provide a treatment that 16 includes at least a first nonyl phenyl ethoxylate and sodium lauroyl sarcosinate to which a 17 second nonyl phenyl ethoxylate, acetylated lanolin alcohol, EDTA, a foam stabilizer, 18 water, and inert polyethylene granules can be added without altering the effectiveness of 19 the treatment.
It is a yet further object of the present invention to provide a treatment that is safe 21 to use.

INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use INVENTOR: William Yarbrough 1 It is yet another object of the present invention to provide such treatment that is 2 topical, can be purchased over the counter, and is economical.
3 IV. SUMMARY OF THE INVENTION
4 The above objects of the invention are provided for in a topical treatment for acne vulgaris. According to the invention, a method is provided for applying a composition of 6 substances to the infected area, working the composition into the infected area, and 7 removing the composition from the infected area. The composition comprises at least 8 one ethoxylate in combination with Sodium Lauroyl Sarcosinate (or "SLS"). An inert 9 scrubbing agent, such as polyethylene beads, can also be included to the formula.
Acetylated lanolin alcohol, a second ethoxylate, EDTA, a foam stabilizer, and water can 11 also be added to the composition without effecting performance.
12 Other formulas that keep the polarity similar to that of the inventive formula will 13 also work. To keep the polarity similar, it is necessary for the compound to have similar 14 characteristics, such as Carbon chains, carbonyl groups, Nitrogen bound to Carbon, Aromatic ring(s), Oxylate groups, and appropriate functional groups at the ends of the 16 individual molecules. The ideal substitute chemicals would have all of the characteristics 17 mentioned above, but it is not necessary to have every one of those as listed. For 18 example, if the functional groups at the ends of the individual molecules are exchanged 19 for other functional groups that retain the ability to undergo an emulsion polymerization, then the effectiveness of the compound is also retained. Another example is to change the 21 ethoxylate to a methoxylate or propoxylate. These formations would still retain a similar INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use INVENTOR: William Yarbrough 1 polarity but would be different compounds with different characteristics.
Yet another 2 example would be to exchange triply bound Nitrogen with a doubly bound or perhaps 3 Nitrogen with 4 Carbons bound to it.
4 V. DETAILED DESCRIPTION OF THE INVENTION
Chemical analysis and research has revealed that two of the component parts of 6 the inventive composition are principally involved in its effectiveness as an acne 7 treatment: an ethoxylate and Sodium Lauroyl Sarcosinate ("SLS"). The ethoxylate is 8 preferably a nonyl phenol ethoxylate.
9 The Inventor has also found, however, that other formulas that keep the polarity similar to that of the inventive formula will also work. To keep the polarity similar, it is 11 necessary for the compound to have similar characteristics, such as Carbon chains, 12 carbonyl groups, Nitrogen bound to Carbon, Aromatic ring(s), Oxylate groups, and 13 appropriate functional groups at the ends of the individual molecules. The ideal 14 substitute chemicals would have all of the characteristics mentioned above, but it is not necessary to have every one of those as listed. For example, if the functional groups at the 16 ends of the individual molecules are exchanged for other functional groups that retain the 17 ability to undergo an emulsion polymerization, then the effectiveness of the compound is 18 also retained. Another example is to change the ethoxylate to a methoxylate or 19 propoxylate. These formations would still retain a similar polarity but would be different compounds with different characteristics. Yet another example would be to exchange INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use INVENTOR: William Yarbrough 1 triply bound Nitrogen with a doubly bound or perhaps Nitrogen with 4 Carbons bound to 2 it.
3 The inventor has also discovered that the addition of an inert scrubbing agent 4 improves the action of the inventive composition. The beads should be large enough to be effective but not so large as to cause abrasions. The inventor suggests beads in the 6 range of 5 to SO microns with an average size being approximately 25 microns or 50 7 mesh.
8 To make the inventive composition, an exact ratio of ethoxylate to SLS is not 9 critical. The only requirement is that the ethoxylate is completely reacted with the SLS, creating a polymer. This will vary with the ethoxylate used, but the Inventor has 11 determined that a ratio of ethoxylate-to- SLS of 1. S :2 is preferred. The amount by weight 12 of polyethylene beads can vary according to the grittiness desired. The Inventor has 13 found that a formula of ethoxylate:SLS:polyethylene of 40:20:40 is preferred but that 14 formulas of other concentrations are useful. Thus, for production purposes, formulas having SLS ranging from 10 to 20 % by weight, ethoxylate ranging from 20 to 40 % by 16 weight, and polyethylene beads from 20 to 50% by weight are reasonable. But again, the 17 formula is not restricted to these ranges, which ranges are presented for example purposes 18 only.
19 Also, a cutting agent that does not chemically react with the composition may be added. The cutting agent makes the overall composition flow more easily, thereby INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use INVENTOR: William Yarbrough 1 enabling more packaging options, such as tubes. The cutting agent must be added only in 2 sufficient amount that it promotes flow but does not effect the action of the composition.
3 In use, an sufficient amount of the composition is used to cover the infected area, 4 the composition is applied to an infected area and worked over the area by a scrubbing motion. After sufficient time has elapsed to ensure that the infected area has been 6 adequately exposed to the composition such that they area feels clean, approximately ten 7 to thirty seconds for the typical person, the area is rinsed cleaned.

Claims (32)

I CLAIM:
1. A Treatment for Acne Vulgaris comprising sodium lauroyl sarcosinate and a nonyl phenyl ethoxylate in combination.
2. The treatment for Acne Vulgaris of Claim 1 further including a second nonyl phenyl ethoxylate.
3. The treatment for Acne Vulgaris of Claim 1 further including acetylated lanolin alcohol.
4. The treatment for Acne Vulgaris of Claim 1 further including polyethylene granules.
5. The treatment for Acne Vulgaris of Claim 1 further including water.
6. The treatment for Acne Vulgaris of Claim 1 further including ethylenediaminetetraacetic acid.
7. The treatment for Acne Vulgaris of Claim 1 further including a foam stabilizing agent.
8. The treatment for Acne Vulgaris of Claim 1 further including a cutting agent.
9. The cutting agent of Claim 8 being selected from the group of aqueous based solutions and oil based solutions.
10. The treatment for Acne Vulgaris of Claim 1 wherein the ethoxylate is exchanged for a methoxylate.
11. The treatment for Acne Vulgaris of Claim 1 wherein the ethoxylate is exchanged for a propoxylate.
12. A treatment for Acne Vulgaris comprising an ethoxylate, sodium lauroyl sarcosinate, and scrubbing means.
13. The treatment for Acne Vulgaris of Claim 12 wherein the scrubbing mean is polyethylene beads.
14. The treatment for Acne Vulgaris of Claim 12 further including a cutting agent.
15. The treatment for Acne Vulgaris of Claim 12 wherein the ethoxylate is exchanged for a methoxylate.
16. The treatment for Acne Vulgaris of Claim 12 wherein the ethoxylate is exchanged for a propoxylate.
17. A treatment for Acne Vulgaris comprising: a first ethoxylate, a second ethoxylate, acetylated lanolin alcohol, sodium lauroyl sarcosinate, EDTA, a foam stabilizer, water, and inert polyethylene granules.
18. The treatment for Acne Vulgaris of Claim 17 wherein the first ethoxylate is exchanged for a methoxylate.
19. The treatment for Acne Vulgaris of Claim 17 wherein the first ethoxylate is exchanged for a propoxylate.
20. A treatment for Acne Vulgaris comprising an ethoxylate, sodium lauroyl sarcosinate, and EDTA.
21. The treatment for Acne Vulgaris of Claim 20 wherein the ethoxylate is exchanged for a methoxylate.
22. The treatment for Acne Vulgaris of Claim 20 wherein the ethoxylate is exchanged for a propoxylate.
23. A method for treating Acne Vulgaris comprising the steps of:
preparing a composition comprising an ethoxylate and sodium lauroyl sarcosinate;
applying the composition to an infected area;
permitting the composition to remain on the infected area a sufficient amount of time to enable the composition of matter to cause an effect; and, removing the composition from the infected area.
24. The method of Claim 23 wherein preparing the composition further includes adding second ethoxylate.
25. The method of Claim 23 wherein preparing the composition further includes adding acetylated lanolin alcohol.
26. The method of Claim 23 wherein preparing the composition further includes adding acetylated polyethylene granules.
27. The method of Claim 23 wherein preparing the composition further includes adding water.
28. The method of Claim 23 wherein preparing the composition further includes EDTA.
29. The method of Claim 23 wherein preparing the composition further includes a foam stabilizer.
30. The method of Claim 23 further including the step of adding a thinning agent to the composition.
31. The method of Claim 23 wherein the ethoxylate is exchanged for a methoxylate.
32. The method of Claim 23 wherein the ethoxylate is exchanged for a propoxylate.
CA002535550A 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use Abandoned CA2535550A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/025207 WO2005018629A1 (en) 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use

Publications (1)

Publication Number Publication Date
CA2535550A1 true CA2535550A1 (en) 2005-03-03

Family

ID=34215304

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002535550A Abandoned CA2535550A1 (en) 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use

Country Status (5)

Country Link
EP (1) EP1656128A4 (en)
JP (1) JP2007521234A (en)
AU (1) AU2003264053A1 (en)
CA (1) CA2535550A1 (en)
WO (1) WO2005018629A1 (en)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2557090A3 (en) 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
FR2923383B1 (en) * 2007-11-08 2010-03-19 Oreal USE OF AN N-ACYLATED SARCOSINATE AS A MICROBIAL ANTI-ADHESION AGENT.
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
JP2011525476A (en) 2008-03-05 2011-09-22 アブリンクス エン．ヴェー． Novel antigen-binding dimer complex, its production method and use
EP2947097A1 (en) 2008-04-07 2015-11-25 Ablynx N.V. Amino acid sequences directed against the Notch pathways and uses thereof
CN102099378B (en) 2008-05-16 2016-01-20 埃博灵克斯股份有限公司 For CXCR4 and other GPCRs aminoacid sequence and comprise the polypeptide of described aminoacid sequence
WO2009147248A2 (en) 2008-06-05 2009-12-10 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US9005963B2 (en) 2008-10-14 2015-04-14 Ablynx N.V. Amino acid sequences directed against cellular receptors for viruses and bacteria
EP2364328A2 (en) 2008-12-10 2011-09-14 Ablynx NV Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
BRPI1013877A2 (en) 2009-04-10 2017-08-15 Ablynx Nv IMPROVED AMINO ACID SEQUENCES AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS
EP2424889B1 (en) 2009-04-30 2015-08-12 Ablynx N.V. Method for the production of domain antibodies
SMT201700376T1 (en) 2009-06-05 2017-09-07 Ablynx Nv Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
PT2473527T (en) 2009-09-03 2017-02-27 Ablynx Nv Stable formulations of polypeptides and uses thereof
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP3309176A1 (en) 2009-12-14 2018-04-18 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CA2787718C (en) 2010-02-11 2018-05-15 Ablynx Nv Methods and compositions for the preparation of aerosols
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
PH12012502272A1 (en) 2010-05-20 2017-07-26 Ablynx Nv Biological materials related to her3
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
EP2632946B1 (en) 2010-10-29 2017-12-06 Ablynx N.V. Method for the production of immunoglobulin single variable domains
RS59589B1 (en) 2010-11-05 2019-12-31 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain
CU24111B1 (en) 2010-11-08 2015-08-27 Novartis Ag POLYPEPTIDES THAT LINK TO CXCR2
CA2831415A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Bispecific anti-cxcr7 immunoglobulin single variable domains
WO2012130872A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
EP3590950A1 (en) 2011-05-09 2020-01-08 Ablynx NV Method for the production of immunoglobulin single varible domains
WO2012163887A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
IN2014CN00437A (en) 2011-06-23 2015-04-03 Ablynx Nv
AU2012311443B2 (en) 2011-09-23 2016-12-01 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
PL2773671T3 (en) 2011-11-04 2022-01-24 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
JP6351572B2 (en) 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Heteromultimeric constructs of immunoglobulin heavy chains with mutations in the Fc domain
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
JP6603209B2 (en) 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ Protein modification of living cells using sortase
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
HUE044199T2 (en) 2014-10-10 2019-10-28 Ablynx Nv Inhalation device for use in aerosol therapy of respiratory diseases
JP2017538779A (en) 2014-10-10 2017-12-28 アブリンクス・エヌ・フェー Method for treating RSV infection
ES2772348T3 (en) 2014-12-19 2020-07-07 Ablynx Nv Nanobody dimers with cysteine linkages
EP3380517B1 (en) 2015-11-27 2021-08-04 Ablynx NV Polypeptides inhibiting cd40l
SE543153C2 (en) 2016-05-19 2020-10-13 Biocool Ab Aqueous hydrogen peroxide solution obtained from a dry composition comprising sodium percarbonate for skin treatment
CA3026108A1 (en) 2016-06-10 2017-12-14 Clarity Cosmetics Inc. Non-comedogenic hair and scalp care formulations and method for use
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
CN117700549A (en) 2016-11-16 2024-03-15 埃博灵克斯股份有限公司 T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
JP7186401B2 (en) 2017-02-28 2022-12-09 フエー・イー・ベー・フエー・ゼツト・ウエー Means and methods for oral delivery of proteins
US11891451B2 (en) 2017-05-11 2024-02-06 Vib Vzw Glycosylation of variable immunoglobulin domains
CN118085076A (en) 2017-06-02 2024-05-28 埃博灵克斯股份有限公司 Immunoglobulin binding to aggrecan
BR112019025147A2 (en) 2017-06-02 2020-06-23 Merck Patent Gmbh POLYPEPTIDS THAT BIND ADAMTS5, MMP13 AND AGGRECAN
US12129308B2 (en) 2017-06-02 2024-10-29 Merck Patent Gmbh MMP13 binding immunoglobulins
PT3630847T (en) 2017-06-02 2024-11-21 Merck Patent Gmbh Adamts binding immunoglobulins
WO2019016237A1 (en) 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
US11873347B2 (en) 2017-10-31 2024-01-16 Vib Vzw Antigen-binding chimeric proteins and methods and uses thereof
US11999797B2 (en) 2018-02-06 2024-06-04 Ablynx N.V. Methods of treating initial episode of TTP with immunoglobulin single variable domains
US11858960B2 (en) 2018-03-01 2024-01-02 Vrije Universiteit Brussel Human PD-L1-binding immunoglobulins
CA3088676A1 (en) 2018-03-23 2019-09-26 Universite Libre De Bruxelles Wnt signaling agonist molecules
JP7603600B2 (en) 2019-03-08 2024-12-20 リンクシス ベスローテン フェンノートシャップ Internalizing binding molecules that target receptors involved in cell proliferation or cell differentiation
EP3976650A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
WO2020239934A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
JP2023523600A (en) 2020-04-22 2023-06-06 マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド Single variable domain antibodies and derivatives thereof targeting human programmed cell death ligand 1 (PD-L1)
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2022060223A1 (en) 2020-09-16 2022-03-24 Linxis B.V. Internalizing binding molecules
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
EP4216943A1 (en) 2020-09-24 2023-08-02 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
WO2022175392A1 (en) 2021-02-17 2022-08-25 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
CA3209052A1 (en) 2021-02-19 2022-08-25 Rafael Cristian CASELLAS Single domain antibodies that neutralize sars-cov-2
WO2022242892A1 (en) 2021-05-17 2022-11-24 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
US20240360189A1 (en) 2021-07-09 2024-10-31 Luxembourg Institute Of Health (Lih) Dimeric protein complexes and uses thereof
IL317461A (en) 2022-06-08 2025-02-01 Tidal Therapeutics Inc Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024008274A1 (en) 2022-07-04 2024-01-11 Universiteit Antwerpen T regulatory cell modification
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024137731A2 (en) 2022-12-21 2024-06-27 Genzyme Corporation Anti‑pd‑1×4‑1bb binding proteins
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
WO2024156888A1 (en) 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
WO2024231348A1 (en) 2023-05-11 2024-11-14 Vib Vzw Slc4a4/nbce1 inhibitors
WO2024251783A1 (en) 2023-06-05 2024-12-12 Sanofi Predicting thermal stabilities of immunoglobulin single variable domains using machine-learning models
EP4483951A1 (en) 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
US12138428B1 (en) 2024-01-24 2024-11-12 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
US12144969B1 (en) 2024-02-28 2024-11-19 Sanofi Attachment mechanism, module and assembly herewith
US12186538B1 (en) 2024-05-10 2025-01-07 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
US12213944B1 (en) 2024-05-16 2025-02-04 Genzyme Corporation Fluid transfer device
US12171719B1 (en) 2024-05-16 2024-12-24 Genzyme Corporation Fluid transfer device
US12226371B1 (en) 2024-05-16 2025-02-18 Genzyme Corporation Fluid transfer device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539031A (en) * 1975-02-22 1979-01-24 Beecham Group Ltd Pharmaceutical compositions
US4147782A (en) * 1976-06-24 1979-04-03 William H. Rorer, Inc. Pharmaceutical detergent composition
AU5318399A (en) * 1998-07-20 2000-02-07 Victor Chamberlain Acne treatment compositions
US6423746B1 (en) * 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use
US7008963B2 (en) * 1999-07-03 2006-03-07 The William M. Yarbrough Foundation Urushiol induced contact dermatitis solution

Also Published As

Publication number Publication date
EP1656128A4 (en) 2007-02-28
EP1656128A1 (en) 2006-05-17
AU2003264053A1 (en) 2005-03-10
WO2005018629A1 (en) 2005-03-03
JP2007521234A (en) 2007-08-02

Similar Documents

Publication Publication Date Title
CA2535550A1 (en) Treatment for acne vulgaris and method of use
US6423746B1 (en) Urushiol induced contact dermatitis and method of use
CA2256960C (en) High glycerin containing anti-microbial cleansers
US4395398A (en) Dental hemostatic composition
US9730870B2 (en) Sodium hypochlorite-based body wash compositions
MX2007005444A (en) Topical pharmaceutical compositions containing an antiacne compound and antibiotic compound.
US10561626B2 (en) Method for treating urushiol induced contact dermatitis
KR20110043661A (en) Antimicrobial Gel Formulations
US20160317577A1 (en) Electrolyzed saline redox-balanced compositions and methods for treating skin conditions
MXPA06001668A (en) Treatment for acne vulgaris and method of use
JP4298866B2 (en) Dechlorinating agent
WO2002002104A1 (en) Urushiol induced contact dermatitis treatment and method of use
CN111743793A (en) Hand sanitizer and preparation method thereof
JP2668853B2 (en) Kitchen detergent
WO2000069403A1 (en) Alpha amino acid composition and method for the treatment of skin
JP3293692B2 (en) Fungicide composition for sandbox containing iodine
JP2002332237A (en) External preparation for skin
WO2004052358A1 (en) Urushiol induced contact dermatitis treatment and method of use
JP2007502289A (en) Compositions for the treatment of biting and invasive organisms, parasites and urticaria, and methods of use
US20050037039A1 (en) Composition for treatment of tinea pedis and method of use
JP2000143440A (en) Bactericidal agent comprising string-shaped giant micelle
JPH07233041A (en) Skin external preparation
PL194901B1 (en) Method of obtaining a gel-type antiacneic preparation
CN85106029A (en) A kind ofly can remove pigmented spots, freckle, promote the pure white cosmetics materials of skin
TH17177A (en) Topical formulation containing water

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead